November 14, 2025
2 min watch
ORLANDO — In this video from the American Academy of Ophthalmology meeting, Diana V. Do, MD, discusses the real-world use of aflibercept 8 mg in wet age-related macular degeneration or diabetic macular edema.
A study of data from the IRIS Registry looked at how clinicians use Eylea HD (aflibercept 8 mg, Regeneron) in patients with treatment-naive wet AMD or DME and patients who had received prior treatment with Eylea (aflibercept 2 mg, Regeneron) before switching to Eylea HD.
In treatment-naive patients, the injection interval could be extended to 12 weeks in DME and wet AMD after administration of aflibercept 8 mg. In those who originally received aflibercept 2 mg, the injection interval could be extended by an additional 2 weeks with stable vision.
“This is very useful information for clinicians as we learn how to use aflibercept 8 mg in our clinical practice,” Do, vice chair of clinical affairs and professor at the Byers Eye Institute at Stanford University, said.
Sources/Disclosures
Source:
Healio Interviews
Disclosures:
Do reports consulting for 4DMT, Adverum, Apellis Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Belite Bio, Boehringer Ingelheim, EyePoint, Genentech, Iveric Bio, Kodiak Sciences, Kriya Therapeutics, LumiThera, Regeneron and Regenxbio; receiving grant support from Belite Bio, Boehringer Ingelheim, LumiThera, Regeneron and Regenxbio; and holding stock in Belite Bio and Kodiak Sciences.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
